{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-263722","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2026-06-09T20:05:20+00:00","discovered_at":"2026-06-09T20:07:00.365463+00:00","generated_at":"2026-06-09T20:13:48.821962+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Stockholders approve Amended and Restated 2018 Equity Incentive Plan adding 1.76M new shares plus annual increases","bullets":["Plan approved with 11.14M for, 433K against; adds 1,756,257 new shares to reserve plus annual 5% increases from 2027-2036.","Directors Paul B. Manning and Lawrence Eichenfield re-elected with 11.54M and 11.52M votes for, respectively.","Advisory vote on executive compensation passed with 11.56M for, 34K against.","Ratification of KPMG LLP as independent auditor for fiscal year 2026 approved with 14.06M for.","Plan effective immediately upon stockholder approval on June 5, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-263722","json":"https://secwatch.observer/filing/0001193125-26-263722.json","markdown":"https://secwatch.observer/filing/0001193125-26-263722.md","text":"https://secwatch.observer/filing/0001193125-26-263722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/0001193125-26-263722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/d139416d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T20:13:48.821962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09e4a5814844b784f0bac6c1966b282eb1b2f219","claim":"Verrica Pharmaceuticals Inc. shareholders approved Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan in the form attached as Appendix A to the Proxy Statement. at the 2026-06-05 meeting.","evidence_excerpt":"Proposal No. 4 : Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan in the form attached as Appendix A to the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Approval of the Company’s Amended and Restated 2018 Equity Incentive Plan 11,142,881 433,852 36,469 Broker Non-Votes: 2,456,129","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/0001193125-26-263722-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"},{"claim_id":"32cd88bf3fd8b9ba67cea1f23ed2992c4c56bc37","claim":"Verrica Pharmaceuticals Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. at the 2026-06-05 meeting.","evidence_excerpt":"Proposal No. 1 : Election of two nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Paul B. Manning 11,543,142 70,060 Lawrence Eichenfield 11,523,540 89,662 Broker Non-Votes: 2,456,129. All nominees were elected.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/0001193125-26-263722-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"},{"claim_id":"4b8b6312eb512b892bb51373acdda42fdec7d9b8","claim":"Verrica Pharmaceuticals Inc. shareholders approved Ratification of the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-05 meeting.","evidence_excerpt":"Proposal No. 3 : Ratification of the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of selection of KPMG LLP 14,058,234 8,055 3,042","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/0001193125-26-263722-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"},{"claim_id":"900d741887f06c37d1efefd0250e3300eaf9a657","claim":"Verrica Pharmaceuticals Inc. shareholders approved Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. at the 2026-06-05 meeting.","evidence_excerpt":"Proposal No. 2 : Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 11,564,256 34,355 14,591 Broker Non-Votes: 2,456,129.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/0001193125-26-263722-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-05"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}